araag2/HINT huggingface dataset:
Clinical trial NCT03271541 (phase 2, status: completed)
Conditions: beta-thalassemia
ICD codes: D56.1, D56.2, D56.5, D57.42, D57.44, D57.432, D57.439
Drugs: bitopertin
SMILES: C[C@H](OC1=CC=C(C=C1C(=O)N1CCN(CC1)C1=C(F)C=C(C=N1)C(F)(F)F)S(C)(=O)=O)C(F)(F)F
Eligibility criteria:

        Inclusion Criteria:

          -  Confirmed diagnosis of beta-thalassemia

          -  Clinically defined non-transfusion-dependent anemia (Part 1 only), defined as Hb
             concentrations >7.5 grams per deciliter (g/dL) and <9.5 g/dL, less than or equal to 4
             transfusions of red blood cell units within 1 year prior to study enrollment, and no
             transfusion within 12 weeks prior to study enrollment

          -  Completion of 16 weeks of treatment with bitopertin in Part 1 of this study with more
             than 80% compliance from expected use of study medication (based on patient diary and
             study drug accountability; Part 2 only)

          -  A favorable benefit-risk ratio from treatment with bitopertin as assessed by the
             Investigator (Part 2 only)

        Exclusion Criteria:

          -  Any history of gene therapy

          -  History of hemolytic anemia except for beta-thalassemia

          -  Severe symptomatic splenomegaly and/or hepatomegaly with hypersplenism (Part 1 only)

          -  Any use of an erythropoiesis-stimulating agent within 24 weeks prior to enrollment.

          -  Initiation of iron chelation therapy or hydroxyurea within 24 weeks prior to
             enrollment (Part 1 only)

          -  Depression, treatment with anti-depressants, or other psychiatric illnesses and/or
             drug abuse

          -  Clinically significant/uncontrolled comorbid disease

          -  Pregnant or breastfeeding females

          -  Use of cytochrome P450 (CYP) 3A4 inhibitors within 2 weeks or CYP3A4 inducers within 4
             weeks prior to study drug

          -  Active hepatitis B or C or known positive human immunodeficiency virus (HIV) test
             result

          -  Diagnosis of cancer within previous 5 years unless treatment has resulted in complete
             freedom from disease for at least 2 years

          -  Any major illness within 1 month or febrile illness within 1 week prior to study drug

          -  Pulmonary hypertension requiring oxygen therapy (Part 1 only)
Clinical trial NCT03292809 (phase 2/phase 3, status: completed)
Conditions: dry eye disease
ICD codes: H04.121, H04.122, H04.123, H04.129, H35.3111, H35.3112, H35.3121
Drugs: cyclasol topical ocular, eye drops, vehicle topical ocular, eye drops
SMILES: CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O)C(C)C, CC1=CC(O)=CC(C)=C1Cl
Eligibility criteria:

        Inclusion Criteria:

          -  Signed ICF (Informed Consent Form) and HIPAA (Health Insurance Portability and
             Accountability Act)

          -  Patient-reported history of DED in both eyes

          -  Current use of OTC (over-the-counter) and/or artificial tears for dry eye symptoms

          -  Ability and willingness to follow instructions, including participation in all study
             assessments and visits

        Exclusion Criteria:

          -  Women who are pregnant, nursing or planning a pregnancy

          -  Unwillingness to submit a urine pregnancy test at screening and the last visit (or
             early termination visit) if of childbearing potential, or unwillingness to use
             acceptable means of birth control

          -  Clinically significant slit-lamp findings or abnormal lid anatomy at screening

          -  Ocular/periocular malignancy

          -  History of herpetic keratitis

          -  Active ocular allergies or ocular allergies that may become active during the study
             period

          -  Ongoing ocular or systemic infection at screening or baseline

          -  Wear of contact lenses within 3 months prior to screening or anticipated use of
             contact lenses during the study

          -  History of no response to previous topical Cyclosporine A and/or use of topical
             Cyclosporine A or Liftigrast within 2 months prior to screening

          -  Intraocular surgery or ocular laser surgery within the previous 6 months, or have any
             planned ocular and/or lid surgeries over the study period

          -  Presence of uncontrolled systemic diseases

          -  Presence of known allergy and/or sensitivity to the study drug or its components
Clinical trial NCT03300362 (phase 2, status: terminated)
Conditions: influenza
ICD codes: J11.81, J11.82, J10.01, J10.81, J10.82, J11.08, J11.2
Drugs: seasonal influenza vaccine, mva-np+m1, sodium chloride
SMILES: [O-][N+](=O)OCC(CO[N+]([O-])=O)(CO[N+]([O-])=O)CO[N+]([O-])=O, [Na+].[Cl-]
Reason stopped: 
    change to recommended season flu vaccine in uk
  
Eligibility criteria:

        Inclusion Criteria:

          -  Volunteer is willing and has capacity to provide written informed consent for
             participation in the trial (in the Investigator's opinion).

          -  Male or female adults, aged 65 years and above

          -  Able and willing (in the Investigator's opinion) to comply with all study requirements

          -  Willing to allow the investigators to discuss the volunteer's medical history with
             their General Practitioner

          -  Eligible to receive seasonal influenza vaccine

        Exclusion Criteria:

          -  Any history of anaphylaxis in reaction to vaccination or history of allergic reactions
             likely to be exacerbated by any component of the vaccine (e.g. egg allergy)

          -  Ongoing terminal illness with a life expectancy estimated to be approximately <6
             months.

          -  Continuous use of oral anticoagulants, such as coumarins and related anticoagulants
             (i.e. warfarin) or novel oral anticoagulants (i.e. apixaban, rivaroxaban, dabigatran
             and edoxaban)

          -  Any other significant disease, disorder or finding (including blood test results),
             which, in the opinion of the Investigators, would either put the volunteer at risk
             because of participation in the study, or may influence the result of the study

          -  Participation in another clinical trial of an investigational medicinal product in the
             30 days preceding enrolment, or planned use during the study period

          -  Prior receipt of an investigational vaccine likely to impact on interpretation of the
             trial data

          -  Receipt of annual seasonal influenza vaccine prior to enrolment (for the same
             influenza season volunteers are recruited in)

          -  Not willing to comply with study procedures
Clinical trial NCT03311724 (phase 2, status: completed)
Conditions: type 2 diabetes
ICD codes: E11.65, E11.9, E11.21, E11.36, E11.41, E11.42, E11.44
Drugs: tirzepatide, placebo
SMILES: CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  Have type 2 diabetes (T2DM) for ≥6 months according to the Criteria for Diagnosing
             Type 2 Diabetes Mellitus (American Diabetes Association 2017).

          -  Have HbA1c of 7.0% to 10.5%, inclusive, as assessed by the central laboratory.

          -  If on metformin, have been treated with stable doses of metformin for at least 3
             months.

          -  Have a body mass index (BMI) between 23 and 45 kilograms per square meter.

        Exclusion Criteria:

          -  Have type 1 diabetes (T1D).

          -  Have used any glucose-lowering medication other than metformin within 3 months prior
             to study entry or during screening/lead-in period or have used any glucagon-like
             peptide-1 receptor agonists (GLP-1 RAs) at any time in the past 12 months.

          -  Have had any of the following cardiovascular conditions: acute myocardial infarction
             (MI), New York Heart Association Class III or Class IV heart failure, or
             cerebrovascular accident (stroke).

          -  Have acute or chronic hepatitis, signs and symptoms of any other liver disease other
             than nonalcoholic fatty liver disease (NAFLD), or alanine aminotransferase (ALT) level
             >2.5 times the upper limit of the reference range, as determined by the central
             laboratory at study entry; participants with NAFLD are eligible for participation in
             this trial.

          -  Have had chronic or acute pancreatitis any time prior to study entry.

          -  Have an estimated glomerular filtration rate (eGFR) <45 milliliters/minute/1.73 square
             meter, calculated by the Chronic Kidney Disease-Epidemiology (CKD-EPI) equation.

          -  Have serum calcitonin ≥20 picograms per milliliter, as determined by the central
             laboratory at study entry.

          -  Have any condition that is a contraindication for use of the GLP-1 RA class (per
             country-specific labels) at study entry or develop such condition between study entry
             and randomization.
Clinical trial NCT03320941 (phase 2, status: completed)
Conditions: obesity
ICD codes: E66.8, E66.9, E66.1, O99.214, O99.215, O99.210, O99.211
Drugs: lik066, placebo
SMILES: CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  Patients with obesity disease and inadequately controlled body weight with diet and/or
             exercise

          -  BMI ≥ 25 kg/m^2 combined with at least two obesity-related comorbidities, or BMI ≥ 35
             kg/m^2 at least one obesity-related comorbidity

          -  Patients with FPG ≥ 110 mg/dL and/or 5.6% ≤ HbA1c ≤ 10.0%, or T2DM with HbA1c ≤ 10.0%

          -  Waist circumference at umbilical level ≥ 85 cm for male, ≥ 90 cm for female

          -  Visceral fat area ≥ 100 cm^2

          -  Agreement to comply with the study-required life-style intervention and treatment
             during the full duration of the study

        Exclusion Criteria:

          -  Pregnancy or lactating women

          -  Use of pharmacologically active weight-loss medications

          -  Bariatric surgery

          -  Ketoacidosis, lactic acidosis, hyperosmolar coma

          -  Symptomatic genital ingection or urinary tract infection in the 4 weeks prior to
             screening

          -  Gastro-intestinal (GI) disorders associated with chronic diarrhea

          -  Congestive heart failure, New York Heart Association (NYHA) class III or IV
Clinical trial NCT03322137 (phase 2, status: completed)
Conditions: pruritus, psoriasis vulgaris
ICD codes: L29.0, L29.1, L29.2, L29.8, L29.9, L29.3, L40.0
Drugs: sna-120, vehicle
SMILES: CC1=CC(O)=CC(C)=C1Cl
Eligibility criteria:

        Inclusion Criteria:

          -  Informed consent/assent and Health Insurance Portability and Accountability Act
             (HIPAA) authorization

          -  Stable PV for at least 6 months prior to screening

          -  Chronic pruritus of the PV plaques to be present for at least 6 weeks prior to
             screening

          -  Mild to moderate PV at screening and baseline

          -  Has a target plaque at baseline on the trunk and/or limbs

          -  Subject's plaques are amenable to treatment with a topical ointment medication

          -  Willing and able to comply with the study instructions and attend all scheduled study
             visits.

          -  Willing to avoid prolonged exposure of the designated treatment plaques to ultraviolet
             radiation

          -  Females of childbearing potential must have a negative pregnancy test at baseline
             before randomization and must agree to use highly effective contraception during the
             study

          -  Men who are sexually active and can father children must agree to use highly effective
             forms of contraception during the study

        Exclusion Criteria:

          -  Underlying conditions other than psoriasis that, in the opinion of the investigator,
             currently cause or influence pruritus of the overall skin

          -  Positive hepatitis serology

          -  Thyroid abnormalities that may impact itching

          -  Subjects with spontaneously improving or rapidly deteriorating PV and/or pruritus

          -  Current diagnosis of guttate, erythrodermic, exfoliative, or pustular psoriasis

          -  Active psoriasis or itch affecting the palmar/plantar regions

          -  Subjects with a clinical diagnosis of bacterial infection of the skin

          -  Any major medical illness or symptoms of a clinically significant illness that may
             influence the study outcome

          -  Any acute chronic medical or psychiatric condition or laboratory abnormality that
             would make them unsuitable for participation in this study

          -  Known hypersensitivity to the study treatment excipients and /or polyethylene glycol,
             that contraindicates participation

          -  Currently enrolled in an investigational drug or device study or has used an
             investigational drug or an investigational device treatment within 30 days of
             randomization/baseline (Note: Subjects who are enrolled in a long-term follow-up study
             and are not actively receiving an investigational drug or investigational device
             treatment may be eligible for participation in this study)

          -  Female who is pregnant or lactating, or is planning to become pregnant during the
             study

          -  Subjects participating in any previous SNA-120 (and/or CT327) clinical studies
Clinical trial NCT03325010 (phase 2, status: completed)
Conditions: tourette syndrome
ICD codes: F95.2
Drugs: valbenazine, placebo oral capsule
SMILES: COC1=C(OC)C=C2[C@H]3C[C@@H](OC(=O)[C@@H](N)C(C)C)[C@H](CC(C)C)CN3CCC2=C1, CC1=CC(O)=CC(C)=C1Cl
Eligibility criteria:

        Inclusion Criteria:

          1. Have a clinical diagnosis of Tourette Syndrome (TS)

          2. Have at least moderate tic severity

          3. Have TS symptoms that impair school, occupational, and/or social function

          4. If using maintenance medication(s) for TS or TS spectrum diagnoses (e.g.
             obsessive-compulsive disorder [OCD], Attention-Deficit Hyperactivity Disorder [ADHD]),
             be on stable doses

          5. Be in good general health

          6. Adolescent subjects (12 to 17 years of age) must have a negative urine drug screen for
             amphetamines, barbiturates, benzodiazepine, phencyclidine, cocaine, opiates, or
             cannabinoids and a negative alcohol screen

          7. Subjects of childbearing potential who do not practice total abstinence must agree to
             use hormonal or two forms of nonhormonal contraception (dual contraception)
             consistently during the screening, treatment and follow-up periods of the study

        Exclusion Criteria:

          1. Have an active, clinically significant unstable medical condition within 1 month prior
             to screening

          2. Have a known history of long QT syndrome or cardiac arrhythmia

          3. Have a known history of neuroleptic malignant syndrome

          4. Have a cancer diagnosis within 3 years prior to screening (some exceptions allowed)

          5. Have an allergy, hypersensitivity, or intolerance to VMAT2 inhibitors

          6. Have a blood loss ≥250 mL or donated blood within 30 days prior to screening

          7. Have a known history of substance dependence, substance (drug) or alcohol abuse

          8. Have a significant risk of suicidal or violent behavior

          9. Have initiated Comprehensive Behavioral Intervention for Tics (CBIT) during the
             screening period or at baseline or plan to initiate CBIT during the study

         10. Have received an investigational drug within 30 days before screening or plan to use
             an investigational drug (other than NBI-98854) during the study
Clinical trial NCT03339999 (phase 2, status: terminated)
Conditions: plaque psoriasis
ICD codes: L40.0, L40.4, L40.8, L40.9, L40.1, L40.50
Drugs: agn-242428, placebo
SMILES: CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Reason stopped: 
    safety reason
  
Eligibility criteria:

        Inclusion Criteria:

          -  Participants who have a confirmed diagnosis of plaque psoriasis, diagnosed at least 6
             months before study with a Physician's Global Assessment (PGA) score ≥ 3 at screening
             and baseline

          -  Severity of disease must be at least moderate, defined as Psoriasis Area and Severity
             Index (PASI) ≥ 12 and % body surface area (BSA) ≥ 10

          -  Participant is a candidate for phototherapy or systemic therapy for psoriasis

          -  Body weight of at least 55 kilograms (kg) (121 (pound) lbs)

        Exclusion Criteria:

          -  Non-plaque forms of psoriasis (erythrodermic, guttate, pustular) or drug-induced
             psoriasis

          -  Psoriasis which has not been stable for the 4 weeks prior to screening and which is
             unstable at Study Day 1

          -  History of Gilbert's, Rotor, or Dubin-Johnson syndromes or any other disorder of
             bilirubin metabolism

          -  History of active mycobacterium tuberculosis (TB) infection or untreated or
             inadequately treated latent TB

          -  Positive QuantiFERON test for TB infection at screening

          -  Had a vaccination with Bacillus Calmette-Guérin (BCG) within 12 months prior to
             baseline

          -  Positive drug and/or alcohol test at screening (with the exception of marijuana).
             Retesting in the case of a positive alcohol test is allowed at the discretion of the
             sponsor

          -  Current treatment or history of treatment with any anti-Tumor Necrosis Factor alpha
             (TNFα) biologic therapy within 3 months or 5 half-lives of study, and/or all other
             biologics within 6 months of study (Day 1)

          -  Efficacy failure on 2 or more biologic agents for the treatment of psoriasis when the
             failures occurred within 1 year of the initiation of the therapy of the first biologic
             agent

          -  Alanine aminotransferase (ALT), aspartate aminotransferase (AST) or total bilirubin
             (TBL) exceeding 1.5 times the upper limit of normal (ULN) at screening.
Clinical trial NCT03344614 (phase 2, status: unknown status)
Conditions: colorectal cancer
ICD codes: C05.2, C10.0, C16.0, C16.4, C17.0, C17.1, C17.2
Drugs: raltitrexed combined with apatinib
SMILES: [H][C@]12O[C@]3(CC4=CC=CC=C4)O[C@]1(C[C@@]([H])(C)[C@]1(O3)[C@]3([H])C=C(C)C(=O)[C@@]3(O)CC(COC(=O)CC3=CC(OC)=C(O)C=C3)=C[C@@]21[H])C(C)=C
Eligibility criteria:

        Inclusion Criteria:

          -  1.Male or female, ≥ 18 of age;

          -  2.Histological confirmed advanced colorectal adenocarcinoma，and at least one
             measurable lesion;

          -  3.Have failed for ≥ 2 lines of standard chemotherapy(included Fluorouracil, irinotecan
             and oxaliplatin);

          -  4.ECOG performance status 0-2;

          -  5.Life expectancy of more than 3 months;

          -  6.The main organs function is well, and randomized within 14 days before the relevant
             inspection indicators to meet the following requirements:

               1. blood routine test Hgb ﹥90g/L, ANC﹥1.5×109/L, Platelets ﹥ 100×109/L,

               2. biochemical tests Serum Total bilirubin ≤ 1.5 X UNL(upper normal limit), ALT or
                  AST ≤ 2 xUNL, and ﹤ 5 x UNL（Hematogenous metastases）, Creatinine clearance rate≥
                  60 ml/min(Cockcroft-Gault formula),

               3. Doppler echocardiography assessment：LVEF ≥ 50%;

          -  7.No serious heart, lung, liver, kidney dysfunction; no jaundice and gastrointestinal
             obstruction; no acute infection;

          -  8.Signed informed consent;

          -  9.Good compliance, and family members agree to receive survival follow-up.

        Exclusion Criteria:

          -  1.Factors that could have an effect on oral medication (such as inability to swallow,
             chronic diarrhea and intestinal obstruction);
Clinical trial NCT03358290 (phase 2, status: terminated)
Conditions: plaque psoriasis, skin diseases
ICD codes: L40.0, L40.4, L40.8, L40.9, L40.1, L40.50, L99, O99.711, O99.712, O99.713, O99.719, O99.72, O99.73
Drugs: jte-051, placebo
SMILES: CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Reason stopped: 
    difficulty faced with enrollment in the study
  
Eligibility criteria:

        Inclusion Criteria:

          -  Diagnosed with moderate to severe plaque psoriasis at least 6 months prior to Visit 1

          -  Plaque-type psoriasis covering ≥10% of body surface area (BSA) at Visit 1 and Visit 2;

          -  Psoriasis Area and Severity Index (PASI) score ≥12 at Visit 1 and Visit 2;

          -  Static Physician's Global Assessment (sPGA) score ≥3 at Visit 1 and Visit 2;

          -  Body Mass Index (BMI) ≤38 at Visit 1.

        Exclusion Criteria:

          -  Medical history of treatment failure to any systemic agents for plaque psoriasis;

          -  Prior exposure to more than one biologic agent treatment;

          -  Presence of erythrodermic psoriasis, pustular psoriasis, guttate psoriasis,
             medication-induced psoriasis or other skin conditions at (e.g., clinically-significant
             eczema or severe acne) that could interfere with study evaluations at Visit 1;

          -  Presence or history of any itch due to underlying conditions other than plaque
             psoriasis which cause or influence pruritus of the skin (e.g., drug induced pruritus,
             significant other systemic diseases with itch) within 12 months prior to Visit 1;

          -  History of a clinically-significant infection (e.g., that required oral antimicrobial
             therapy) within 8 weeks prior to Visit 2;

          -  History of infections requiring hospitalization or parenteral antibiotic, antiviral,
             antifungal or antiparasitic therapy within 6 months prior to Visit 2 and no history of
             recurrent infections or conditions predisposing to chronic infections (e.g.,
             bronchiectasis, chronic osteomyelitis);

          -  History of or at risk for destructive arthropathy (e.g., rapidly progressing
             osteoarthritis, osteonecrosis, spontaneous osteonecrosis of the knee, subchondral
             insufficiency fracture, hip dislocation and pathologic fracture) at Visit 1.